Evidence map›Paper›PMID 24624365›Full record

Trial reportFrontiers in cellular and infection microbiology2014

Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease.

Murray E Hines, Sue E Turnquist, Marcia R S Ilha, Sreekumari Rajeev, Arthur L Jones, Lisa Whittington, John P Bannantine, Raúl G Barletta, Yrjö T Gröhn, Robab Katani and 3 more

Open access · goldAbstract readClinical TrialComparative Study
In one paragraph

Trial report in Frontiers in cellular and infection microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Vaccines · 2023
    Article
  7. Bioprospective Role ofMolecules (Basel, Switzerland) · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Identification of essential genes inFrontiers in microbiology · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. A Bovine EntericFrontiers in immunology · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Murray E HinesTifton Veterinary Diagnostic and Investigational Laboratory, University of Georgia Tifton, GA, USA.
Sue E TurnquistTifton Veterinary Diagnostic and Investigational Laboratory, University of Georgia Tifton, GA, USA.
Marcia R S IlhaTifton Veterinary Diagnostic and Investigational Laboratory, University of Georgia Tifton, GA, USA.
Sreekumari RajeevTifton Veterinary Diagnostic and Investigational Laboratory, University of Georgia Tifton, GA, USA.
Arthur L JonesCollege of Veterinary Medicine, Food Animal Health and Management Program, University of Georgia Athens, GA, USA.
Lisa WhittingtonTifton Veterinary Diagnostic and Investigational Laboratory, University of Georgia Tifton, GA, USA.
John P BannantineNational Animal Disease Center, United States Department of Agriculture, Agricultural Research Service Ames, IA, USA.
Raúl G BarlettaSchool of Veterinary Medicine and Biomedical Sciences, University of Nebraska Lincoln, NE, USA.
Yrjö T GröhnSection of Epidemiology, Department of Population Medicine and Diagnostic Sciences, Cornell University Ithaca, NY, USA.
Robab KataniDepartment of Veterinary Science, Penn State University, University Park Pennsylvania, PA, USA.
Adel M TalaatDepartment of Pathobiological Sciences, University of Wisconsin-Madison Madison, WI, USA.
Lingling LiDepartment of Veterinary Science, Penn State University, University Park Pennsylvania, PA, USA.
Vivek KapurDepartment of Veterinary Science, Penn State University, University Park Pennsylvania, PA, USA.
University of Georgia · USPennsylvania State University · USNational Animal Disease Center · USUniversity of Nebraska–Lincoln · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 10(9) CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization.

Indexed as

Bacterial VaccinesDisease Models, AnimalGoat DiseasesMycobacterium avium subsp. paratuberculosisParatuberculosisAdministration, OralAnimalsAnimal StructuresBacterial SheddingGoatsVaccinesVaccines, AttenuatedBacterial VaccinesVaccinesVaccines, Attenuateddiagnostic testsgoatsmutant vaccinesMycobacterium avium subsp paratuberculosisvaccine efficacy

Identifiers

PMID24624365
PMCPMC3941644
OpenAlexW2154465974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.